Watt Test / VO2 Max: How Medications Change Your Cardiorespiratory Fitness

What the Watt Test Actually Measures

The Watt test and VO2 max both quantify how efficiently the cardiovascular and respiratory systems deliver and extract oxygen during maximal effort. VO2 max (maximal oxygen consumption) is the gold-standard metric for aerobic capacity, expressed in milliliters of oxygen consumed per kilogram of body weight per minute (mL/kg/min). The Watt test is a cycle-ergometer protocol that estimates VO2 max by recording the peak power output in watts at exhaustion.

Direct vs. Estimated Measurement

Direct VO2 max requires a metabolic cart, a mouthpiece, and gas analysis during a graded exercise test. It is the reference standard described in the 2003 ATS/ACCP Statement on Cardiopulmonary Exercise Testing, which remains the most-cited guideline document for CPET interpretation. [1] The Watt test and similar field protocols (Astrand, Bruce, Balke) estimate VO2 max from power output or heart-rate response, introducing an error of roughly 5 to 10% compared with direct measurement. [2]

Why Relative VO2 Max Matters More Than Absolute

Expressing VO2 max relative to body weight (mL/kg/min) matters for longevity stratification because carrying excess mass reduces the number without changing the heart's actual output capacity. A 110 kg man who loses 10 kg on semaglutide may see his relative VO2 max increase 2 to 4 mL/kg/min even with no change in absolute fitness. This distinction is critical when tracking medication-driven changes.

The MET Equivalence

One metabolic equivalent (1 MET) equals approximately 3.5 mL/kg/min. Physicians and cardiologists often convert VO2 max into METs for clinical communication. A VO2 max of 35 mL/kg/min equals 10 METs. A landmark analysis of 66,371 patients in the Cleveland Clinic database showed that each 1-MET increase in exercise capacity corresponded to a roughly 12% reduction in all-cause mortality. [3]

VO2 Max Normal Ranges and Longevity Targets

Understanding a single VO2 max number requires age- and sex-stratified reference data. A reading that looks "normal" for a sedentary 60-year-old woman may represent significantly reduced longevity potential compared with age-matched active peers.

AHA-Referenced Normal Ranges by Age and Sex

The American Heart Association published sex- and age-stratified VO2 max classifications in its 2016 scientific statement on physical activity and cardiovascular health. [4] Representative values for "above average" fitness by decade (in mL/kg/min):

| Age group | Men "above average" | Women "above average" | |---|---|---| | 20 to 29 | above 46 | above 38 | | 30 to 39 | above 44 | above 36 | | 40 to 49 | above 41 | above 34 | | 50 to 59 | above 38 | above 31 | | 60 to 69 | above 35 | above 28 |

These thresholds derive from epidemiological cohort data and are used by the AHA to stratify cardiovascular risk. Being in the "low" category (bottom quintile for age and sex) carries a relative risk of all-cause mortality roughly double that of the "high" category. [4]

The Longevity-Medicine Target: "Cardiorespiratory Fitness Elite"

Peter Attia's longevity-medicine framework, grounded in the 2022 analysis of 750,302 Veterans Affairs patients published in the Journal of the American College of Cardiology (JACC), places the mortality-risk tipping point at the top two fitness quintiles. [5] Men aged 45 to 54 in the "elite" quintile had a hazard ratio for all-cause mortality of 0.20 compared with those in the "low" quintile. That is an 80% relative risk reduction. Reaching "above average" confers most of the benefit; the incremental gain from "above average" to "elite" is smaller but measurable.

What "Optimal" Means Clinically

"Optimal" for VO2 max is not a single number. Age, sex, and baseline health status all modify the target. For a 50-year-old man undergoing testosterone replacement therapy, a reasonable 12-month target is to move from the "low" quintile (below 33 mL/kg/min) to at least the "above average" quintile (above 38 mL/kg/min), a gain achievable with structured zone-2 training three to five days per week plus medication optimization.

Beta-Blockers and VO2 Max: The Most Clinically Significant Drug Effect

Beta-blockers are the medication class with the largest, most consistent negative effect on measured VO2 max. This matters because millions of patients on beta-blockers for hypertension, heart failure, or post-MI prophylaxis will show artificially suppressed Watt test results.

Mechanism of Heart-Rate Blunting

Beta-adrenergic blockade reduces peak heart rate by 20 to 30 beats per minute during maximal exercise. Because VO2 max depends on cardiac output (heart rate multiplied by stroke volume), blunting heart rate directly lowers the achievable VO2 max. A 1995 Cochrane-reviewed meta-analysis of cardioselective beta-blockers reported a mean reduction in exercise capacity of approximately 8% in patients without heart failure. [6] Non-cardioselective agents (propranolol, carvedilol) produce larger reductions than cardioselective agents (metoprolol, bisoprolol, atenolol).

Interpreting Watt Test Results on Beta-Blockers

A patient on metoprolol succinate 50 mg/day who achieves 180 watts on a Watt test may actually have an underlying aerobic capacity equivalent to 210 to 220 watts. Labs reporting raw Watt-test output without noting beta-blocker use will underestimate true cardiorespiratory fitness by a clinically meaningful margin. The 2003 ATS/ACCP CPET guidelines explicitly state that beta-blocker use must be documented and factored into VO2 max interpretation. [1]

Should Beta-Blockers Be Held Before Testing?

Holding a beta-blocker before a VO2 max test is not universally safe or appropriate. In patients with heart failure with reduced ejection fraction (HFrEF), abrupt withdrawal risks rebound tachycardia and decompensation. The decision should be made by the prescribing cardiologist. For patients on beta-blockers solely for hypertension with preserved EF, 24-hour washout of short-acting agents (e.g., metoprolol tartrate) may allow a more representative test result, but only under physician supervision.

GLP-1 Receptor Agonists: Weight-Mediated Gains in Relative VO2 Max

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) do not directly stimulate cardiac output or skeletal muscle oxygen extraction. Their effect on VO2 max is primarily indirect, mediated by reductions in body mass.

The Weight-Loss Mechanism

Relative VO2 max (mL/kg/min) improves when the denominator (body weight in kg) decreases, even if absolute oxygen consumption stays constant. In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% in the placebo group (P<0.001). [7] A 100 kg man who loses 15 kg and maintains the same absolute VO2 of 3.5 L/min sees his relative VO2 max rise from 35 mL/kg/min to approximately 41 mL/kg/min, a shift from the "low" to the "above average" AHA category.

Direct Cardiac Effects Under Investigation

A 2023 sub-analysis of the SURMOUNT-1 trial (tirzepatide, N=2,539) reported improvements in cardiometabolic biomarkers including resting heart rate, which declined by 1.3 bpm at 72 weeks. [8] Whether GLP-1 agonists produce direct myocardial effects independent of weight loss remains an open research question. The SELECT trial (semaglutide 2.4 mg, N=17,604 patients with established cardiovascular disease) showed a 20% relative risk reduction in major adverse cardiovascular events. [9] Whether improved VO2 max mediates any of that benefit has not been established.

Lean Mass Preservation and Functional VO2 Max

One concern with rapid GLP-1-driven weight loss is loss of lean mass, which reduces skeletal muscle oxidative capacity and may partially offset relative VO2 max gains. A 2022 analysis published in Obesity showed that semaglutide-treated patients lost approximately 39% of total weight loss as lean mass without resistance training. [10] Combining GLP-1 therapy with structured resistance and aerobic training is expected to preserve lean mass and yield larger net VO2 max improvements, though head-to-head data in this specific context remain limited.

Testosterone Replacement Therapy (TRT) and VO2 Max

Testosterone directly influences erythropoiesis, skeletal muscle protein synthesis, and cardiac contractility. Hypogonadal men have measurably lower VO2 max values than eugonadal peers, and TRT partially corrects this deficit.

Mechanisms of VO2 Max Improvement

Testosterone stimulates renal erythropoietin production, raising red blood cell mass and hemoglobin concentration. Higher hemoglobin increases the blood's oxygen-carrying capacity, which raises VO2 max independent of cardiac output changes. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (JCEM) found that testosterone enanthate 200 mg IM every two weeks for 12 weeks increased VO2 max by 3.1 mL/kg/min in hypogonadal men (baseline total testosterone below 300 ng/dL) compared with placebo. [11]

Dose and Duration Considerations

The magnitude of VO2 max improvement with TRT depends on baseline testosterone level, hematocrit response, and concurrent training. Men with baseline testosterone below 200 ng/dL show larger improvements than those starting near the lower limit of normal (300 ng/dL). Hematocrit should be monitored at 3 and 6 months; values above 54% require dose reduction per Endocrine Society guidelines to avoid hyperviscosity. [12]

TRT in Women and VO2 Max

Low-dose testosterone therapy in peri- and postmenopausal women is studied less extensively for VO2 max outcomes. A 2019 Cochrane review of testosterone for women found improvements in sexual function but limited data on aerobic performance. [13] The effect on VO2 max in women using testosterone for androgen insufficiency remains an area requiring further study.

Other Medications with Clinically Meaningful Effects

Diuretics

Loop and thiazide diuretics reduce plasma volume by 5 to 10% acutely. Lower preload reduces stroke volume and cardiac output at maximal exercise, dropping VO2 max by an estimated 2 to 5% in volume-responsive patients. [14] Dehydration as little as 2% of body weight reduces VO2 max by approximately 10% in healthy adults, according to data cited in the 2007 American College of Sports Medicine (ACSM) position stand on exercise and fluid replacement. [15]

Statins and Muscle Performance

Statin-associated myopathy affects 5 to 10% of patients and can reduce exercise tolerance when it causes myalgias or frank myositis. A 2012 meta-analysis in the Journal of the American College of Cardiology found that statins did not significantly alter VO2 max in the absence of myopathy, but patients with statin-induced muscle symptoms showed reduced exercise capacity. [16] Creatine kinase (CK) elevation above 10 times the upper limit of normal warrants statin discontinuation before VO2 max testing.

Inhaled Corticosteroids and Bronchodilators

For patients with asthma or COPD, inhaled corticosteroids alone have minimal effect on VO2 max. Long-acting beta-2 agonists (LABAs) such as salmeterol or formoterol bronchodilate the airways and reduce dynamic hyperinflation, improving VO2 max by 1 to 3 mL/kg/min in obstructive lung disease patients. [17] Systemic corticosteroids (oral prednisone) reduce muscle protein synthesis and VO2 max when used chronically at doses above 10 mg/day.

How to Accurately Interpret a Watt Test on Medications

Getting a meaningful Watt test result while on medications requires careful pre-test documentation and sometimes protocol modification.

Pre-Test Medication Review Protocol

Before any Watt test or CPET, the ordering clinician should document: (1) all beta-blockers and their most recent dose timing, (2) diuretic use and estimated volume status, (3) any statin-associated symptoms, (4) bronchodilator use and timing, and (5) androgen therapy type and dose. Results reported without this context can mislead both patient and clinician.

Adjusting Expected Values by Drug Class

A practical adjustment framework for interpreting raw Watt test output:

• Beta-blocker users: add 8 to 15% to estimated VO2 max to approximate drug-free capacity. [6]
• Diuretic users tested in a dehydrated state: repeat test after adequate hydration before drawing conclusions.
• TRT users (eugonadal range achieved): no adjustment needed. The improved VO2 max reflects genuine physiological improvement.
• GLP-1 users: note the body weight at testing. Serial VO2 max tracking should use consistent body weight documentation to distinguish weight-loss-driven gains from fitness-driven gains.

Serial Testing to Track Medication Response

Single-point VO2 max values are less useful than serial measurements taken 12 and 24 weeks into a medication change or training program. The minimum clinically detectable difference for CPET-measured VO2 max is approximately 1.0 mL/kg/min in trained individuals and 1.5 mL/kg/min in sedentary individuals, based on test-retest reliability data in the ATS/ACCP guidelines. [1] Changes smaller than this threshold may reflect measurement variability rather than true physiological shifts.

Optimizing VO2 Max Alongside Medication Management

Medications rarely substitute for structured training. They create windows of opportunity, less body weight, higher hemoglobin, better bronchodilation, that training must exploit to produce durable VO2 max gains.

Zone-2 Training as the Foundation

Zone-2 aerobic training (60 to 70% of maximum heart rate, conversational pace) drives mitochondrial biogenesis in type-1 muscle fibers and is the primary stimulus for VO2 max improvement in non-elite populations. The HERITAGE Family Study (N=481) showed that 20 weeks of standardized aerobic training produced a mean VO2 max increase of 17%, with responders gaining as much as 30% and non-responders gaining less than 5%. [18] Genetic variation in training response, not medication use, explained most of the variance.

High-Intensity Interval Training for Faster Gains

High-intensity interval training (HIIT) produces VO2 max gains 1.5 to 2 times larger than moderate continuous training in the same total time, based on a 2019 meta-analysis of 86 trials published in the British Journal of Sports Medicine. [19] A practical HIIT protocol for medication-managed patients: four-minute intervals at 85 to 95% of peak heart rate, four repetitions, twice weekly, combined with three zone-2 sessions. This six-session-per-week structure is appropriate once a patient has tolerated at least four weeks of zone-2 base training.

Combined Pharmacological and Training Strategy for GLP-1 Users

GLP-1 receptor agonist therapy combined with structured aerobic training can produce additive VO2 max improvements. Weight loss reduces the mechanical load of exercise, making higher training intensities accessible sooner. Patients on semaglutide 2.4 mg who add 150 minutes per week of moderate-to-vigorous physical activity may reach the "above average" VO2 max category in 6 to 12 months, a combination the lifestyle arm of the STEP-5 trial (104 weeks, N=304) showed was associated with sustained cardiometabolic benefit. [20]